Ontology highlight
ABSTRACT: Background
Despite advances in the treatment of heart failure, mortality remains high, particularly in individuals with diabetes. Activated transforming growth factor beta (TGF-?) contributes to the pathogenesis of the fibrotic interstitium observed in diabetic cardiomyopathy. We hypothesized that high glucose enhances the activity of the transcriptional co-activator p300, leading to the activation of TGF-? via acetylation of Smad2; and that by inhibiting p300, TGF-? activity will be reduced and heart failure prevented in a clinically relevant animal model of diabetic cardiomyopathy.Methods
p300 activity was assessed in H9c2 cardiomyoblasts under normal glucose (5.6 mmol/L-NG) and high glucose (25 mmol/L-HG) conditions. 3H-proline incorporation in cardiac fibroblasts was also assessed as a marker of collagen synthesis. The role of p300 activity in modifying TGF-? activity was investigated with a known p300 inhibitor, curcumin or p300 siRNA in vitro, and the functional effects of p300 inhibition were assessed using curcumin in a hemodynamically validated model of diabetic cardiomyopathy - the diabetic TG m(Ren-2)27 rat.Results
In vitro, H9c2 cells exposed to HG demonstrated increased p300 activity, Smad2 acetylation and increased TGF-? activity as assessed by Smad7 induction (all p ConclusionsThese findings suggest that high glucose increases the activity of the transcriptional co-regulator p300, which increases TGF-? activity via Smad2 acetylation. Modulation of p300 may be a novel strategy to treat diabetes induced heart failure.
SUBMITTER: Bugyei-Twum A
PROVIDER: S-EPMC4108062 | biostudies-literature | 2014 May
REPOSITORIES: biostudies-literature
Bugyei-Twum Antoinette A Advani Andrew A Advani Suzanne L SL Zhang Yuan Y Thai Kerri K Kelly Darren J DJ Connelly Kim A KA
Cardiovascular diabetology 20140505
<h4>Background</h4>Despite advances in the treatment of heart failure, mortality remains high, particularly in individuals with diabetes. Activated transforming growth factor beta (TGF-β) contributes to the pathogenesis of the fibrotic interstitium observed in diabetic cardiomyopathy. We hypothesized that high glucose enhances the activity of the transcriptional co-activator p300, leading to the activation of TGF-β via acetylation of Smad2; and that by inhibiting p300, TGF-β activity will be red ...[more]